Biotech stocks took a bath in this holiday-shortened week. The catalyst was the announcement by Express Scripts (ESRX), the nation’s largest benefits manager, to use AbbVie’s (ABBV) hepatitis C drug exclusively. That hurt Gilead Sciences (GILD), whose stock has soared on sales of its own ground-breaking hepatitis treatment.